The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study
The article presents the experience of 19 Russian medical institutions on the use of eribulin in combination with trastuzumab in various treatment lines of metastatic HER2+ breast cancer in routine clinical practice. Aim. The main objective of this retrospective observational study was to evaluat...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | RU |
| Publicado: |
IP Habib O.N.
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/348c12ae10644482a51e5fd30b93fd11 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:348c12ae10644482a51e5fd30b93fd11 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:348c12ae10644482a51e5fd30b93fd112021-11-30T17:03:34ZThe efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study1815-14341815-144210.26442/18151434.2020.1.200058https://doaj.org/article/348c12ae10644482a51e5fd30b93fd112020-05-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/34173/22585https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442The article presents the experience of 19 Russian medical institutions on the use of eribulin in combination with trastuzumab in various treatment lines of metastatic HER2+ breast cancer in routine clinical practice. Aim. The main objective of this retrospective observational study was to evaluate the efficacy and tolerability of eribulin and trastuzumab combo in HER2+ breast cancer patients pretreated with anthracyclines and taxanes. The analysis included 60 patients who received at least 2 cycles of eribulin in combination with trastuzumab. 2 patients (3.3%) received treatment as the 1st line, as the 2nd 14 (23.3%), as the 3rd 16 (26.7%), and as the 4th and more 28 (46.7%). Materials and methods. Complete response was achieved in 2 (3.3%) patients, partial response in 9 (15%), stable disease in 33 (55%), stabilization for more than 6 months in 11 (18.3%), disease progression was detected in 16 (26.7%) patients. The objective response rate was 18.3% in the whole group, the clinical benefit rate 36.7%. Results. The objective response rate in the group of the luminal subtype (ER/PR+HER2+) was 26.9%, in HER2-overexpressed subtype (ER-PR-HER2+) 8.8% and 64.7%, respectively, disease progression was recorded 2.3 times more often 35.3% versus 15.5% in the luminal subtype group. The median progression-free survival in patients with HER2+ breast cancer was 4.95 months (95% confidence interval CI 3.048.29 months), in luminal subtype 6.38 months (95% CI 3.338.54 months), in non-luminal 4.44 months (95% CI 2.47.96 months); p=0.306. The treatment was well tolerated, the spectrum of adverse events corresponded to the eribulin toxicity profile. Conclusions. The uniqueness of this study lies in the fact that on a large clinical material from the standpoint of real clinical practice, a very promising treatment regimen that is not used routinely in a number of countries has been studied, its effectiveness and satisfactory tolerance have been confirmed.Elena I. KovalenkoElena V. ArtamonovaElena V. KarabinaIrina I. AndreiashkinaEkaterina A. Prokof’evaNataliia O. PopovaElena A. GaisinaIrina V. EvstigneevaMikhail V. ShaidorovLarisa A. ZhiliaevaDmitrii M. PonomarenkoAlfiia I. KhasanovaGuzel Z. MukhametshinaAnton E. KoziakovLiudmila V. VorotilinaAnton Iu. PovyshevElena I. SimolinaVasilii V. MarfutovDmitrii V. KozlovIrina R. SuslovaValentina E. ShikinaTatiana V. KarandeevaArtem O. Shepel’Liudmila V. KramskaiaDenis A. OskirkoOlga S. FrolovaIP Habib O.N.articlebreast cancereribulinefficacytoleranceNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 22, Iss 1, Pp 53-59 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
RU |
| topic |
breast cancer eribulin efficacy tolerance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
breast cancer eribulin efficacy tolerance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Elena I. Kovalenko Elena V. Artamonova Elena V. Karabina Irina I. Andreiashkina Ekaterina A. Prokof’eva Nataliia O. Popova Elena A. Gaisina Irina V. Evstigneeva Mikhail V. Shaidorov Larisa A. Zhiliaeva Dmitrii M. Ponomarenko Alfiia I. Khasanova Guzel Z. Mukhametshina Anton E. Koziakov Liudmila V. Vorotilina Anton Iu. Povyshev Elena I. Simolina Vasilii V. Marfutov Dmitrii V. Kozlov Irina R. Suslova Valentina E. Shikina Tatiana V. Karandeeva Artem O. Shepel’ Liudmila V. Kramskaia Denis A. Oskirko Olga S. Frolova The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study |
| description |
The article presents the experience of 19 Russian medical institutions on the use of eribulin in combination with trastuzumab in various treatment lines of metastatic HER2+ breast cancer in routine clinical practice.
Aim. The main objective of this retrospective observational study was to evaluate the efficacy and tolerability of eribulin and trastuzumab combo in HER2+ breast cancer patients pretreated with anthracyclines and taxanes. The analysis included 60 patients who received at least 2 cycles of eribulin in combination with trastuzumab. 2 patients (3.3%) received treatment as the 1st line, as the 2nd 14 (23.3%), as the 3rd 16 (26.7%), and as the 4th and more 28 (46.7%).
Materials and methods. Complete response was achieved in 2 (3.3%) patients, partial response in 9 (15%), stable disease in 33 (55%), stabilization for more than 6 months in 11 (18.3%), disease progression was detected in 16 (26.7%) patients. The objective response rate was 18.3% in the whole group, the clinical benefit rate 36.7%.
Results. The objective response rate in the group of the luminal subtype (ER/PR+HER2+) was 26.9%, in HER2-overexpressed subtype (ER-PR-HER2+) 8.8% and 64.7%, respectively, disease progression was recorded 2.3 times more often 35.3% versus 15.5% in the luminal subtype group. The median progression-free survival in patients with HER2+ breast cancer was 4.95 months (95% confidence interval CI 3.048.29 months), in luminal subtype 6.38 months (95% CI 3.338.54 months), in non-luminal 4.44 months (95% CI 2.47.96 months); p=0.306. The treatment was well tolerated, the spectrum of adverse events corresponded to the eribulin toxicity profile.
Conclusions. The uniqueness of this study lies in the fact that on a large clinical material from the standpoint of real clinical practice, a very promising treatment regimen that is not used routinely in a number of countries has been studied, its effectiveness and satisfactory tolerance have been confirmed. |
| format |
article |
| author |
Elena I. Kovalenko Elena V. Artamonova Elena V. Karabina Irina I. Andreiashkina Ekaterina A. Prokof’eva Nataliia O. Popova Elena A. Gaisina Irina V. Evstigneeva Mikhail V. Shaidorov Larisa A. Zhiliaeva Dmitrii M. Ponomarenko Alfiia I. Khasanova Guzel Z. Mukhametshina Anton E. Koziakov Liudmila V. Vorotilina Anton Iu. Povyshev Elena I. Simolina Vasilii V. Marfutov Dmitrii V. Kozlov Irina R. Suslova Valentina E. Shikina Tatiana V. Karandeeva Artem O. Shepel’ Liudmila V. Kramskaia Denis A. Oskirko Olga S. Frolova |
| author_facet |
Elena I. Kovalenko Elena V. Artamonova Elena V. Karabina Irina I. Andreiashkina Ekaterina A. Prokof’eva Nataliia O. Popova Elena A. Gaisina Irina V. Evstigneeva Mikhail V. Shaidorov Larisa A. Zhiliaeva Dmitrii M. Ponomarenko Alfiia I. Khasanova Guzel Z. Mukhametshina Anton E. Koziakov Liudmila V. Vorotilina Anton Iu. Povyshev Elena I. Simolina Vasilii V. Marfutov Dmitrii V. Kozlov Irina R. Suslova Valentina E. Shikina Tatiana V. Karandeeva Artem O. Shepel’ Liudmila V. Kramskaia Denis A. Oskirko Olga S. Frolova |
| author_sort |
Elena I. Kovalenko |
| title |
The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study |
| title_short |
The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study |
| title_full |
The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study |
| title_fullStr |
The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study |
| title_full_unstemmed |
The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study |
| title_sort |
efficacy of the combination of eribulin and trastuzumab in advanced her2-positive breast cancer: the results of russian observational study |
| publisher |
IP Habib O.N. |
| publishDate |
2020 |
| url |
https://doaj.org/article/348c12ae10644482a51e5fd30b93fd11 |
| work_keys_str_mv |
AT elenaikovalenko theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT elenavartamonova theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT elenavkarabina theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT irinaiandreiashkina theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT ekaterinaaprokofeva theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT nataliiaopopova theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT elenaagaisina theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT irinavevstigneeva theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT mikhailvshaidorov theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT larisaazhiliaeva theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT dmitriimponomarenko theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT alfiiaikhasanova theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT guzelzmukhametshina theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT antonekoziakov theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT liudmilavvorotilina theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT antoniupovyshev theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT elenaisimolina theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT vasiliivmarfutov theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT dmitriivkozlov theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT irinarsuslova theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT valentinaeshikina theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT tatianavkarandeeva theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT artemoshepel theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT liudmilavkramskaia theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT denisaoskirko theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT olgasfrolova theefficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT elenaikovalenko efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT elenavartamonova efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT elenavkarabina efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT irinaiandreiashkina efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT ekaterinaaprokofeva efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT nataliiaopopova efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT elenaagaisina efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT irinavevstigneeva efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT mikhailvshaidorov efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT larisaazhiliaeva efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT dmitriimponomarenko efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT alfiiaikhasanova efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT guzelzmukhametshina efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT antonekoziakov efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT liudmilavvorotilina efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT antoniupovyshev efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT elenaisimolina efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT vasiliivmarfutov efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT dmitriivkozlov efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT irinarsuslova efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT valentinaeshikina efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT tatianavkarandeeva efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT artemoshepel efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT liudmilavkramskaia efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT denisaoskirko efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy AT olgasfrolova efficacyofthecombinationoferibulinandtrastuzumabinadvancedher2positivebreastcancertheresultsofrussianobservationalstudy |
| _version_ |
1718406370836873216 |